Document is current
Any future updates will be listed below
-
Authors
Sadeqi Nezhad, Muhammad
Harris, Chris R.
Prela, Orjola
Narrow, Wade
Breitenbach, Mitchell
Wang, Lan
Jain, Shubhrika
Becker, Jennifer L.
Bagci, Buket
Hao, Yansheng
Hezel, Aram F.
Gerber, Scott A.
Mello, Stephano
Withers, Tracy
Carpizo, Darren R.
-
Funding
Funding for this research was provided by:
U of R | Medical Center, University of Rochester (NA)
U of R | Medical Center, University of Rochester (NA)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA295861)
- License Information
-
More Information
Article History
Received: 6 March 2026
Revised: 27 June 2026
Accepted: 15 July 2026
First Online: 1 August 2026
Ethics
Competing interests: MSN is the founder of KAHF Biotech, Inc., and DRC and AFH serve as advisors with equity interests in KAHF Biotech, Inc. KAHF Biotech, Inc. is a biotechnology company developing innovative cancer therapeutics. All other authors declare no competing interests.
Ethical approval: All animal studies were conducted in accordance with institutional and national guidelines for the care and use of laboratory animals and were approved by the University of Rochester’s University Committee on Animal Resources (UCAR), which serves as the Institutional Animal Care and Use Committee (IACUC; protocol no. 2020-008E).
